Gerard Notario
About
Gerard Notario is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Infectious Diseases.
According to data from OpenAlex, Gerard Notario has authored 32 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Epidemiology, 16 papers in Pulmonary and Respiratory Medicine and 11 papers in Infectious Diseases. Recurrent topics in Gerard Notario's work include Pneumonia and Respiratory Infections (15 papers), Respiratory viral infections research (14 papers) and Neonatal Respiratory Health Research (11 papers). Gerard Notario is often cited by papers focused on Pneumonia and Respiratory Infections (15 papers), Respiratory viral infections research (14 papers) and Neonatal Respiratory Health Research (11 papers). Gerard Notario collaborates with scholars based in United States, Germany and United Kingdom. Gerard Notario's co-authors include Todd Busman, Leonid Heifets, J. Carl Craft, Robert Palmér, Colleen Wegzyn, Mark A. Pierce, H Jablonowski, Gary P. Wormser, Bienvenido G. Yangco and Joseph G. Jemsek and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.
In The Last Decade
Gerard Notario
32 papers receiving 857 citations
Peers
Gerard Notario
Graham Mills New Zealand
Edward A. Dominguez United States
Patrizia D’Argenio Italy
Agnès Meybeck France
Subhash Chaudhary United States
F. Schlaeffer Israel
Pere Saballs Spain
Mauro Codeluppi Italy
Christopher Schriever United States
A Bourrillon France
Citations per year, relative to Gerard Notario Gerard Notario (= 1×)
peers
Graham Mills
Countries citing papers authored by Gerard Notario
Since
Specialization
Citations
This map shows the geographic impact of Gerard Notario's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerard Notario with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerard Notario more than expected).
Fields of papers citing papers by Gerard Notario
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gerard Notario. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerard Notario. The network helps show where Gerard Notario may publish in the future.
Co-authorship network of co-authors of Gerard Notario
This figure shows the co-authorship network connecting the top 25 collaborators of Gerard Notario. A scholar is included among the top collaborators of Gerard Notario based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerard Notario. Gerard Notario is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Notario, Gerard, et al.. (2018). Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina. Bosnian Journal of Basic Medical Sciences. 18(3). 279–288.
2.
Tulloh, Robert, Constancio Medrano, Paul A. Checchia, et al.. (2017). CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiology in the Young. 27(8). 1504–1521.
3.
Notario, Gerard, et al.. (2016). The Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe. Infectious Diseases and Therapy. 5(2). 125–137.
4.
Straňák, Zbyněk, Élie Saliba, Klara M. Posfay‐Barbe, et al.. (2016). Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI). PLoS ONE. 11(6). e0157446–e0157446.
5.
Anderson, Evan J., Xavier Carbonell‐Estrany, Maarten O. Blanken, et al.. (2016). Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. The Pediatric Infectious Disease Journal. 36(2). 160–167.
6.
Whelan, Barbara, et al.. (2016). Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs & Therapy Perspectives. 32(3). 119–130.
7.
Al‐Alaiyan, Saleh, Paul Pollack, & Gerard Notario. (2015). Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs in Context. 4. 1–10.
8.
Mori, Masaaki, Masafumi Onodera, Akira Morimoto, et al.. (2014). Palivizumab Use In Japanese Infants And Children With Immunocompromised Conditions. The Pediatric Infectious Disease Journal. 33(11). 1183–1185.
9.
Notario, Gerard, et al.. (2013). Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis. Pulmonary Pharmacology & Therapeutics. 26(6). 666–671.
10.
Namazova-Baranova, Leyla S., et al.. (2012). A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Research Notes. 5(1). 484–484.
11.
Gotfried, Mark H., et al.. (2005). Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Current Medical Research and Opinion. 21(2). 245–254.
12.
Chiu, Yi‐Lin, et al.. (2005). A pooled analysis of seven randomized crossover studiesof the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years. Clinical Therapeutics. 27(12). 1950–1960.
13.
Busman, Todd, et al.. (2003). Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Current Medical Research and Opinion. 19(5). 411–420.
14.
Bonvehí, Pablo, et al.. (2003). Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in???an Era of Drug-Resistant Streptococcus pneumoniae. Clinical Drug Investigation. 23(8). 491–501.
15.
Busman, Todd, et al.. (2003). Comparison of 5 days of extended-release clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study in adolescent and adult patients. Current Medical Research and Opinion. 19(5). 421–429.
16.
Gotfried, Mark H., et al.. (2002). A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clinical Therapeutics. 24(5). 736–751.
17.
Sokol, William N., et al.. (2002). A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clinical Therapeutics. 24(4). 605–615.
18.
Benson, Constance A., Paige L. Williams, David L. Cohn, et al.. (2000). Clarithromycin or Rifabutin Alone or in Combination for Primary Prophylaxis ofMycobacterium aviumComplex Disease in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 181(4). 1289–1297.
19.
Murray, John, et al.. (2000). Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clinical Therapeutics. 22(12). 1421–1432.
20.
Pierce, Mark A., Sheri L. Crampton, David Henry, et al.. (1996). A Randomized Trial of Clarithromycin as Prophylaxis against DisseminatedMycobacterium aviumComplex Infection in Patients with Advanced Acquired Immunodeficiency Syndrome. New England Journal of Medicine. 335(6). 384–391.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Graham Mills Breakdown of academic impact, for papers by Edward A. Dominguez Breakdown of academic impact, for papers by Patrizia D’Argenio Breakdown of academic impact, for papers by Agnès Meybeck Breakdown of academic impact, for papers by Subhash Chaudhary Breakdown of academic impact, for papers by F. Schlaeffer Breakdown of academic impact, for papers by Pere Saballs Breakdown of academic impact, for papers by Mauro Codeluppi Breakdown of academic impact, for papers by Christopher Schriever Breakdown of academic impact, for papers by A Bourrillon